BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease (DKD), hitting a primary endpoint of a phase ...
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ET A) antagonist, SC0062, met the 12-week primary endpoint of a reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results